Selected research
Industry Growth & Trends
Global Anti-obesity Medicine Industry Growth and Trends Forecast to 2032
Market perspective
According to APO Research, the global Anti-obesity Medicine market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for Anti-obesity Medicine is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for Anti-obesity Medicine is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Anti-obesity Medicine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global companies in the Anti-obesity Medicine market include Eisai, Novo Nordisk, Merck, Roche, Pfizer, GlaxoSmithKline, Vivus, Orexigen Therapeutics and Boehringer Ingelheim, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global Anti-obesity Medicine market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Anti-obesity Medicine market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Anti-obesity Medicine market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Anti-obesity Medicine.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global Anti-obesity Medicine market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Anti-obesity Medicine Market by Company
Eisai
Novo Nordisk
Merck
Roche
Pfizer
GlaxoSmithKline
Vivus
Orexigen Therapeutics
Boehringer Ingelheim
Arena Pharmaceuticals
Amylin Pharmaceuticals
Alizyme
Anti-obesity Medicine Segment by Type
Prescription Drugs
OTC Drugs
Anti-obesity Medicine Segment by Application
Men
Women
Anti-obesity Medicine Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anti-obesity Medicine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Anti-obesity Medicine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anti-obesity Medicine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Anti-obesity Medicine companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Prescription Drugs
- OTC Drugs
Applications
- Men
- Women
Companies covered
- Eisai
- Novo Nordisk
- Merck
- Roche
- Pfizer
- GlaxoSmithKline
- Vivus
- Orexigen Therapeutics
- Boehringer Ingelheim
- Arena Pharmaceuticals
- Amylin Pharmaceuticals
- Alizyme
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global Anti-obesity Medicine Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global Anti-obesity Medicine Market Size by Region (2021-2032)
- 1.4.1 Global Anti-obesity Medicine Market Size by Region (2021-2026)
- 1.4.2 Global Anti-obesity Medicine Market Size by Region (2027-2032)
- 1.5 Key Regions Anti-obesity Medicine Market Size (2021-2032)
- 1.5.1 North America Anti-obesity Medicine Market Size Growth Rate (2021-2032)
- 1.5.2 Europe Anti-obesity Medicine Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific Anti-obesity Medicine Market Size Growth Rate (2021-2032)
- 1.5.4 South America Anti-obesity Medicine Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa Anti-obesity Medicine Market Size Growth Rate (2021-2032)
2 Anti-obesity Medicine Market by Type
- 2.1 Type Introduction
- 2.1.1 Prescription Drugs
- 2.1.2 OTC Drugs
- 2.2 Global Anti-obesity Medicine Market Size by Type
- 2.2.1 Global Anti-obesity Medicine Market Size Overview by Type (2021-2032)
- 2.2.2 Global Anti-obesity Medicine Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global Anti-obesity Medicine Market Size Forecasted by Type (2027-2032)
- 2.3 Global Anti-obesity Medicine Market Size by Regions
- 2.3.1 North America Anti-obesity Medicine Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe Anti-obesity Medicine Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific Anti-obesity Medicine Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America Anti-obesity Medicine Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa Anti-obesity Medicine Market Size Breakdown by Type (2021-2026)
3 Anti-obesity Medicine Market by Application
- 3.1 Type Introduction
- 3.1.1 Men
- 3.1.2 Women
- 3.2 Global Anti-obesity Medicine Market Size by Application
- 3.2.1 Global Anti-obesity Medicine Market Size Overview by Application (2021-2032)
- 3.2.2 Global Anti-obesity Medicine Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global Anti-obesity Medicine Market Size Forecasted by Application (2027-2032)
- 3.3 Global Anti-obesity Medicine Market Size by Regions
- 3.3.1 North America Anti-obesity Medicine Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe Anti-obesity Medicine Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific Anti-obesity Medicine Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America Anti-obesity Medicine Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa Anti-obesity Medicine Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 Anti-obesity Medicine Industry Trends
- 4.2 Anti-obesity Medicine Industry Drivers
- 4.3 Anti-obesity Medicine Industry Opportunities and Challenges
- 4.4 Anti-obesity Medicine Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by Anti-obesity Medicine Revenue (2021-2026)
- 5.2 Global Anti-obesity Medicine Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global Anti-obesity Medicine Key Company Headquarters & Area Served
- 5.4 Global Anti-obesity Medicine Company, Product Type & Application
- 5.5 Global Anti-obesity Medicine Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global Anti-obesity Medicine Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 Anti-obesity Medicine Players Market Share by Revenue in 2025
- 5.6.3 2025 Anti-obesity Medicine Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 Eisai
- 6.1.1 Eisai Company Information
- 6.1.2 Eisai Business Overview
- 6.1.3 Eisai Anti-obesity Medicine Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 Eisai Anti-obesity Medicine Product Portfolio
- 6.1.5 Eisai Recent Developments
- 6.2 Novo Nordisk
- 6.2.1 Novo Nordisk Company Information
- 6.2.2 Novo Nordisk Business Overview
- 6.2.3 Novo Nordisk Anti-obesity Medicine Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 Novo Nordisk Anti-obesity Medicine Product Portfolio
- 6.2.5 Novo Nordisk Recent Developments
- 6.3 Merck
- 6.3.1 Merck Company Information
- 6.3.2 Merck Business Overview
- 6.3.3 Merck Anti-obesity Medicine Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 Merck Anti-obesity Medicine Product Portfolio
- 6.3.5 Merck Recent Developments
- 6.4 Roche
- 6.4.1 Roche Company Information
- 6.4.2 Roche Business Overview
- 6.4.3 Roche Anti-obesity Medicine Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 Roche Anti-obesity Medicine Product Portfolio
- 6.4.5 Roche Recent Developments
- 6.5 Pfizer
- 6.5.1 Pfizer Company Information
- 6.5.2 Pfizer Business Overview
- 6.5.3 Pfizer Anti-obesity Medicine Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 Pfizer Anti-obesity Medicine Product Portfolio
- 6.5.5 Pfizer Recent Developments
- 6.6 GlaxoSmithKline
- 6.6.1 GlaxoSmithKline Company Information
- 6.6.2 GlaxoSmithKline Business Overview
- 6.6.3 GlaxoSmithKline Anti-obesity Medicine Revenue, Global Share and Gross Margin (2021-2026)
- 6.6.4 GlaxoSmithKline Anti-obesity Medicine Product Portfolio
- 6.6.5 GlaxoSmithKline Recent Developments
- 6.7 Vivus
- 6.7.1 Vivus Company Information
- 6.7.2 Vivus Business Overview
- 6.7.3 Vivus Anti-obesity Medicine Revenue, Global Share and Gross Margin (2021-2026)
- 6.7.4 Vivus Anti-obesity Medicine Product Portfolio
- 6.7.5 Vivus Recent Developments
- 6.8 Orexigen Therapeutics
- 6.8.1 Orexigen Therapeutics Company Information
- 6.8.2 Orexigen Therapeutics Business Overview
- 6.8.3 Orexigen Therapeutics Anti-obesity Medicine Revenue, Global Share and Gross Margin (2021-2026)
- 6.8.4 Orexigen Therapeutics Anti-obesity Medicine Product Portfolio
- 6.8.5 Orexigen Therapeutics Recent Developments
- 6.9 Boehringer Ingelheim
- 6.9.1 Boehringer Ingelheim Company Information
- 6.9.2 Boehringer Ingelheim Business Overview
- 6.9.3 Boehringer Ingelheim Anti-obesity Medicine Revenue, Global Share and Gross Margin (2021-2026)
- 6.9.4 Boehringer Ingelheim Anti-obesity Medicine Product Portfolio
- 6.9.5 Boehringer Ingelheim Recent Developments
- 6.10 Arena Pharmaceuticals
- 6.10.1 Arena Pharmaceuticals Company Information
- 6.10.2 Arena Pharmaceuticals Business Overview
- 6.10.3 Arena Pharmaceuticals Anti-obesity Medicine Revenue, Global Share and Gross Margin (2021-2026)
- 6.10.4 Arena Pharmaceuticals Anti-obesity Medicine Product Portfolio
- 6.10.5 Arena Pharmaceuticals Recent Developments
- 6.11 Amylin Pharmaceuticals
- 6.11.1 Amylin Pharmaceuticals Company Information
- 6.11.2 Amylin Pharmaceuticals Business Overview
- 6.11.3 Amylin Pharmaceuticals Anti-obesity Medicine Revenue, Global Share and Gross Margin (2021-2026)
- 6.11.4 Amylin Pharmaceuticals Anti-obesity Medicine Product Portfolio
- 6.11.5 Amylin Pharmaceuticals Recent Developments
- 6.12 Alizyme
- 6.12.1 Alizyme Company Information
- 6.12.2 Alizyme Business Overview
- 6.12.3 Alizyme Anti-obesity Medicine Revenue, Global Share and Gross Margin (2021-2026)
- 6.12.4 Alizyme Anti-obesity Medicine Product Portfolio
- 6.12.5 Alizyme Recent Developments
7 North America
- 7.1 North America Anti-obesity Medicine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America Anti-obesity Medicine Market Size by Country (2021-2026)
- 7.3 North America Anti-obesity Medicine Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe Anti-obesity Medicine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe Anti-obesity Medicine Market Size by Country (2021-2026)
- 8.3 Europe Anti-obesity Medicine Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Anti-obesity Medicine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific Anti-obesity Medicine Market Size by Country (2021-2026)
- 9.3 Asia-Pacific Anti-obesity Medicine Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America Anti-obesity Medicine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America Anti-obesity Medicine Market Size by Country (2021-2026)
- 10.3 South America Anti-obesity Medicine Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Anti-obesity Medicine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa Anti-obesity Medicine Market Size by Country (2021-2026)
- 11.3 Middle East & Africa Anti-obesity Medicine Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst